<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03159624</url>
  </required_header>
  <id_info>
    <org_study_id>F140612003</org_study_id>
    <nct_id>NCT03159624</nct_id>
  </id_info>
  <brief_title>Nasal Septal Flap for Donor Site Reconstruction</brief_title>
  <official_title>Use of Porcine Small Intestinal Submucosa (SIS) Graft to Aid in Nasal Septal Remucosalization and Tissue Healing in Patients Following Use of Nasoseptal Flap Elevation for Skull Base Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cook Group Incorporated</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate the utility of porcine small intestinal submucosa
      (SIS) as a graft material that may aid in the natural healing process of freshly exposed bone
      and cartilage in the nasal cavity.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients who undergo endoscopic endonasal skull base surgery, and may require nasoseptal flap
      placement as part of skull base reconstruction, will be informed, consented and enrolled for
      participation. If the intraoperative decision is ultimately made for harvest and placement of
      full-length nasoseptal flap by each individual surgeon, patients will then be consecutively,
      sequentially randomized to use of either:

        -  Thin Doyle silastic sheet placement alone over the resulting exposed septum
           cartilage/bone (20 randomly assigned patients)

        -  2x3 cm Biodesign™ SIS perforated mesentery graft surface placement plus overlying Doyle
           silastic sheet placement over the resulting exposed septum cartilage/bone. (20 randomly
           assigned patients)

      When used, Biodesign graft will be soaked in sterile saline out of the packaging, and placed
      as an intact single sheet over the exposed bone nasal septum bone/cartilage (without
      trimming). For uniformity and ease of future analysis, the bottom edge of the graft will be
      placed parallel to, and proximal to, the nasal floor cut edge remnant mucosal surface as
      possible. Except for a thin Doyle silastic sheet to cover the graft site, no additional
      reinforcement (suture/tissue glue) will be placed for those patients in the Biodesign graft
      arm.

      Time Points and Study Parameters:

        -  All enrolled patients will have Doyle silastic sheeting removed only at 2 weeks post-op.

        -  All patients will receive 250cc normal saline topical nasal rinses starting at 14 days
           until 120 days post-op.

        -  No topical irrigation additives (budesonide/mupirocin) will be administered over 12
           weeks.

      All patients will be assessed at 2 weeks, 6 weeks and 12 weeks following randomization and
      entry into this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 13, 2014</start_date>
  <completion_date type="Actual">March 21, 2016</completion_date>
  <primary_completion_date type="Actual">March 21, 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Change in Post-operative Remucosalization at the Donor Site</measure>
    <time_frame>2 weeks, 6 weeks, 12 weeks</time_frame>
    <description>Mean change as measured by Visual Analogue Scale (VAS) scores from 3 independent reviewers from endoscopy videos collected at 2, 6, and 12 weeks. The Visual Analogue Scale for mean change in post-operative remucosalization is a Likert scale ranging from 0% (no remucosalization) to 100% (complete remucosalization), with higher scores representing better healing.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Change in Post-operative Locoregional Crusting at Donor Site</measure>
    <time_frame>2 weeks, 6 weeks, 12 weeks</time_frame>
    <description>Mean change as measured by Visual Analogue Scale (VAS) scores from 3 independent reviewers from endoscopy videos collected at 2, 6, and 12 weeks. The Visual Analogue Scale for mean change in post-operative crusting is a Likert scale ranging from 0 (no crusting) to 10 (complete crusting), with lower scores representing better healing.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Change in Post-operative Edema at the Donor Site</measure>
    <time_frame>2 weeks, 6 weeks, 12 weeks</time_frame>
    <description>Mean change as measured by Visual Analogue Scale (VAS) scores from 3 independent reviewers from endoscopy videos collected at 2, 6, and 12 weeks. The Visual Analogue Scale for mean change in post-operative edema is a Likert scale ranging from 0 (no edema) to 10 (severe edema), with lower scores representing better healing.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">47</enrollment>
  <condition>Nasal Septum Perforation</condition>
  <arm_group>
    <arm_group_label>Treatment Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2x3 cm Biodesign™ SIS graft placement + overlying Doyle silastic sheet placement over the resulting exposed septum cartilage/bone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Thin Doyle silastic sheet placement alone over the resulting exposed septum cartilage/bone</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Biodesign™ SIS graft</intervention_name>
    <description>2x3 cm Biodesign™ SIS perforated mesentery graft</description>
    <arm_group_label>Treatment Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Doyle silastic sheet</intervention_name>
    <description>Doyle silastic sheet</description>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_label>Treatment Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Elective transnasal endoscopic skull base surgery where closure with a large
             nasoseptal flap (NSF) is anticipated (exposure of &gt;75% of the ipsilateral nasal septum
             bone/cartilage)

          -  Patients without nutritional compromise or otherwise debilitated

          -  Patients who are able to consent for themselves

        Exclusion Criteria:

          -  Bilateral nasoseptal flap (NSF) placement in the same operative setting

          -  Patients without significant bone/cartilage exposure to incorporate an intact 2x3 cm
             graft

          -  Patients requiring 24 hour supplemental oxygen via nasal cannula

          -  Patients who cannot consent for themselves
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brad Woodworth, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>May 17, 2017</study_first_submitted>
  <study_first_submitted_qc>May 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 19, 2017</study_first_posted>
  <results_first_submitted>March 4, 2019</results_first_submitted>
  <results_first_submitted_qc>August 13, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">September 16, 2019</results_first_posted>
  <last_update_submitted>August 13, 2019</last_update_submitted>
  <last_update_submitted_qc>August 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alabama at Birmingham</investigator_affiliation>
    <investigator_full_name>Brad Woodworth, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>nasoseptal flap</keyword>
  <keyword>tissue repair</keyword>
  <keyword>wound healing</keyword>
  <keyword>remucosalization</keyword>
  <keyword>upper airway</keyword>
  <keyword>granulation tissue</keyword>
  <keyword>tissue graft</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nasal Septal Perforation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treatment Group</title>
          <description>2x3 cm Biodesign™ SIS graft placement + overlying Doyle silastic sheet placement over the resulting exposed septum cartilage/bone
Biodesign™ SIS graft: 2x3 cm Biodesign™ SIS perforated mesentery graft
Doyle silastic sheet: Doyle silastic sheet</description>
        </group>
        <group group_id="P2">
          <title>Control Group</title>
          <description>Thin Doyle silastic sheet placement alone over the resulting exposed septum cartilage/bone
Doyle silastic sheet: Doyle silastic sheet</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment Group</title>
          <description>2x3 cm Biodesign™ SIS graft placement + overlying Doyle silastic sheet placement over the resulting exposed septum cartilage/bone
Biodesign™ SIS graft: 2x3 cm Biodesign™ SIS perforated mesentery graft
Doyle silastic sheet: Doyle silastic sheet</description>
        </group>
        <group group_id="B2">
          <title>Control Group</title>
          <description>Thin Doyle silastic sheet placement alone over the resulting exposed septum cartilage/bone
Doyle silastic sheet: Doyle silastic sheet</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="21"/>
            <count group_id="B2" value="26"/>
            <count group_id="B3" value="47"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Change in Post-operative Remucosalization at the Donor Site</title>
        <description>Mean change as measured by Visual Analogue Scale (VAS) scores from 3 independent reviewers from endoscopy videos collected at 2, 6, and 12 weeks. The Visual Analogue Scale for mean change in post-operative remucosalization is a Likert scale ranging from 0% (no remucosalization) to 100% (complete remucosalization), with higher scores representing better healing.</description>
        <time_frame>2 weeks, 6 weeks, 12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment Group</title>
            <description>2x3 cm Biodesign™ SIS graft placement + overlying Doyle silastic sheet placement over the resulting exposed septum cartilage/bone
Biodesign™ SIS graft: 2x3 cm Biodesign™ SIS perforated mesentery graft
Doyle silastic sheet: Doyle silastic sheet</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Thin Doyle silastic sheet placement alone over the resulting exposed septum cartilage/bone
Doyle silastic sheet: Doyle silastic sheet</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Post-operative Remucosalization at the Donor Site</title>
          <description>Mean change as measured by Visual Analogue Scale (VAS) scores from 3 independent reviewers from endoscopy videos collected at 2, 6, and 12 weeks. The Visual Analogue Scale for mean change in post-operative remucosalization is a Likert scale ranging from 0% (no remucosalization) to 100% (complete remucosalization), with higher scores representing better healing.</description>
          <units>percentage of remucosalization</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>2 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.8" lower_limit="40.3" upper_limit="55.3"/>
                    <measurement group_id="O2" value="37.8" lower_limit="31.1" upper_limit="44.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.7" lower_limit="41.6" upper_limit="57.8"/>
                    <measurement group_id="O2" value="43.5" lower_limit="36.7" upper_limit="50.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.9" lower_limit="63.8" upper_limit="83.9"/>
                    <measurement group_id="O2" value="65.3" lower_limit="56.97" upper_limit="73.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>overall change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.1" lower_limit="52.1" upper_limit="62.2"/>
                    <measurement group_id="O2" value="48.9" lower_limit="45.1" upper_limit="52.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Change in Post-operative Locoregional Crusting at Donor Site</title>
        <description>Mean change as measured by Visual Analogue Scale (VAS) scores from 3 independent reviewers from endoscopy videos collected at 2, 6, and 12 weeks. The Visual Analogue Scale for mean change in post-operative crusting is a Likert scale ranging from 0 (no crusting) to 10 (complete crusting), with lower scores representing better healing.</description>
        <time_frame>2 weeks, 6 weeks, 12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment Group</title>
            <description>2x3 cm Biodesign™ SIS graft placement + overlying Doyle silastic sheet placement over the resulting exposed septum cartilage/bone
Biodesign™ SIS graft: 2x3 cm Biodesign™ SIS perforated mesentery graft
Doyle silastic sheet: Doyle silastic sheet</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Thin Doyle silastic sheet placement alone over the resulting exposed septum cartilage/bone
Doyle silastic sheet: Doyle silastic sheet</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Post-operative Locoregional Crusting at Donor Site</title>
          <description>Mean change as measured by Visual Analogue Scale (VAS) scores from 3 independent reviewers from endoscopy videos collected at 2, 6, and 12 weeks. The Visual Analogue Scale for mean change in post-operative crusting is a Likert scale ranging from 0 (no crusting) to 10 (complete crusting), with lower scores representing better healing.</description>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>2 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.50" lower_limit="2.99" upper_limit="4.01"/>
                    <measurement group_id="O2" value="4.22" lower_limit="3.50" upper_limit="4.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.22" lower_limit="3.03" upper_limit="5.41"/>
                    <measurement group_id="O2" value="5.2" lower_limit="4.17" upper_limit="6.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.64" lower_limit="1.48" upper_limit="3.80"/>
                    <measurement group_id="O2" value="2.92" lower_limit="2.17" upper_limit="3.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>overall change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.45" lower_limit="2.97" upper_limit="3.93"/>
                    <measurement group_id="O2" value="4.11" lower_limit="3.63" upper_limit="4.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Change in Post-operative Edema at the Donor Site</title>
        <description>Mean change as measured by Visual Analogue Scale (VAS) scores from 3 independent reviewers from endoscopy videos collected at 2, 6, and 12 weeks. The Visual Analogue Scale for mean change in post-operative edema is a Likert scale ranging from 0 (no edema) to 10 (severe edema), with lower scores representing better healing.</description>
        <time_frame>2 weeks, 6 weeks, 12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment Group</title>
            <description>2x3 cm Biodesign™ SIS graft placement + overlying Doyle silastic sheet placement over the resulting exposed septum cartilage/bone
Biodesign™ SIS graft: 2x3 cm Biodesign™ SIS perforated mesentery graft
Doyle silastic sheet: Doyle silastic sheet</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Thin Doyle silastic sheet placement alone over the resulting exposed septum cartilage/bone
Doyle silastic sheet: Doyle silastic sheet</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Post-operative Edema at the Donor Site</title>
          <description>Mean change as measured by Visual Analogue Scale (VAS) scores from 3 independent reviewers from endoscopy videos collected at 2, 6, and 12 weeks. The Visual Analogue Scale for mean change in post-operative edema is a Likert scale ranging from 0 (no edema) to 10 (severe edema), with lower scores representing better healing.</description>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>2 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.34" lower_limit="2.94" upper_limit="3.75"/>
                    <measurement group_id="O2" value="3.52" lower_limit="3.16" upper_limit="3.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.25" lower_limit="2.74" upper_limit="3.76"/>
                    <measurement group_id="O2" value="3.15" lower_limit="2.75" upper_limit="3.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.26" lower_limit="1.84" upper_limit="2.70"/>
                    <measurement group_id="O2" value="2.65" lower_limit="2.11" upper_limit="3.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>overall change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.95" lower_limit="2.73" upper_limit="3.18"/>
                    <measurement group_id="O2" value="3.11" lower_limit="2.86" upper_limit="3.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Treatment Group</title>
          <description>2x3 cm Biodesign™ SIS graft placement + overlying Doyle silastic sheet placement over the resulting exposed septum cartilage/bone
Biodesign™ SIS graft: 2x3 cm Biodesign™ SIS perforated mesentery graft
Doyle silastic sheet: Doyle silastic sheet</description>
        </group>
        <group group_id="E2">
          <title>Control Group</title>
          <description>Thin Doyle silastic sheet placement alone over the resulting exposed septum cartilage/bone
Doyle silastic sheet: Doyle silastic sheet</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>minor septal perforation</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="21"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>development of transverse synechiae between septum and inferior turbinate</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Brad Woodworth</name_or_title>
      <organization>University of Alabama at Birmingham</organization>
      <phone>205-801-7858</phone>
      <email>bwoodworth@uabmc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

